BASL Partners

Thank you to all our Partner organisations

Novo Nordisk company information:

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit www.novonordisk.co.uk 

Novo Nordisk are sponsoring the following BASL Conferences and Events in 2026:
BASL Annual Meeting
HCC-UK Annual Conference
Basic Science Retreat Meeting
BASL X-tra Online Conference
MASLD Special Interest Group
Rare Liver Diseases Masterclass
School of Hepatology Meeting
Introduction to Hepatology Meeting

Ipsen U.K and Ireland company information:

Ipsen U.K. & Ireland are a core part of Ipsen’s global biopharmaceutical business and is driven by the belief that patients don’t have time to wait. We have a biotech mindset coupled with pharmaceutical capabilities, spanning the early stages of R&D through to in-house manufacturing.

Our business focuses on oncology, rare diseases and neurosciences to create innovative therapies in areas of high unmet medical need. Our licensed medicines and R&D are all focused on improving the lives of patients, with the aim of bringing real value to patients and the healthcare community at every step of the treatment pathway.

CRSC-GB-000402 | January 2026

Ipsen are sponsoring the following BASL Conferences and Events in 2026:
BASL Annual Meeting
HCC-UK Annual Conference
Basic Science Retreat Meeting
BASL X-tra Online Conference
A Special Interest Group
Rare Liver Diseases Masterclass
School of Hepatology Meeting
Introduction to Hepatology Meeting

Madrigal Pharmaceuticals company information:

Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, the need for liver transplant and premature mortality.

What began as a small team of researchers in Conshohocken, Pennsylvania, U.S., is now a fully integrated biopharmaceutical company with more than 900 employees in the United States and Europe with a UK team headquartered in Paddington, London.

United by a single purpose—to lead the fight against MASH—Madrigal has built the leading clinical development program in this field.

Madrigal aims to support health systems and patients living with MASH through our innovations before the devastating complications of advanced liver disease occur. By partnering with healthcare providers and the patient community, we aim to educate, empower and advocate for those impacted by MASH.

MED-UK--2600007| Date of preparation: March 2026

Madrigal are sponsoring the following BASL Conferences and Events in 2026:
BASL Annual Meeting
BASL X-tra Online Conference
MASLD Special Interest Group